CD40LG and neoplasm: Serum IgM and IgG levels were not altered by DT2216 treatment either from normal or tumor-bearing mice after an extended treatment of 5 weeks (Supplementary Fig. 9j, k), as compared with the elevated levels from pristane-treated mice (Supplementary Fig. 9j, k).